Close Menu

NEW YORK (360Dx) – Leerink today upgraded its rating for shares of T2 Biosystems to Outperfrom from Market Perform and raised the target price to $12 from $5, following the US Food and Drug Administration's clearance of the firm's T2Bacteria Panel.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.